C-squared Pharma

Activities: Ingredients

Trending Articles

  1. FDA approves AstraZeneca's FASENRA for hypereosinophilic syndrome AstraZeneca's FASENRA has received FDA approval for hypereosinophilic syndrome in adults and adolescents aged 12 and above, based on Phase III NATRON trial data showing a 65%...
  2. MHRA approves every-four-week dosing regimen for Chiesi's Elfabrio in stable adult Fabry disease patients The firm has received MHRA approval for an additional 2 mg/kg every-four-week dosing regimen for pegunigalsidase alfa, halving the number of annual infusions required for...
  3. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with...
  4. embecta completes £100m acquisition of UK-based Owen Mumford to bolster drug delivery portfolio US diabetes care company embecta has finalised its acquisition of Owen Mumford, gaining access to the Aidaptus next-generation auto-injector platform as it accelerates its...
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Wearable pumps and subcutaneous delivery: a new frontier in heart failure management Two recent developments are reshaping how drug delivery technology can move treatment out of the clinic and into patients’ everyday lives — with implications for both...

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

Related Content

Manufacturing

C2 PHARMA receives CEP approval for Oxybuprocaine hydrochloride

C2 PHARMA proudly announces the approval of a Certificate of Suitability (CEP) for Oxybuprocaine hydrochloride by the European Directorate for the Quality of Medicines and Health Care (EDQM)
Manufacturing

C2 PHARMA marks 10 years at CPHI Milan with expanded ophthalmic APIs

The complany is ready to showcase its expanding ophthalmic API portfolio and global regulatory filings, featuring Naphazoline Hydrochloride and Tropicamide
Ingredients

C2 PHARMA expands ophthalmic API portfolio with Naphazoline Hydrochloride launch

C2 PHARMA, the global leader in ophthalmic and niche active pharmaceutical ingredients (APIs), proudly announces the launch of its latest API, Naphazoline Hydrochloride
Regulatory

C2 Pharma's Tropicamide receives CEP from the European Directorate

The CEP approval of the ophthalmic drug allows C2 Pharma to distribute Tropicamide globally
Ingredients

C2 PHARMA announces upcoming launch of new oxybuprocaine hydrochloride API

C2 PHARMA excited to announce the upcoming launch of its new API, oxybuprocaine HCL, an ingredient that will be manufactured by manufacturing partner Laurus Labs
Ingredients

C2 Pharma to participate in DCAT Week 2024

The C2 PHARMA team will be located in the Benjamin hotel in Suite 2202
Ingredients

C2 PHARMA receives DMF approval in China for pilocarpine nitrate

C2 PHARMA announces the approval of a C-DMF for pilocarpine nitrate — granted on 30 October 2023 — an API manufactured by our Brazilian partner Anidro do Brasil
Subscribe now